New hope for tough head and neck cancers: targeted drug trial opens

NCT ID NCT06857279

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called HLX43 in people whose head and neck cancer has returned or spread to other parts of the body. The drug works by targeting a protein (PD-L1) on cancer cells to help the immune system attack them. About 167 adults aged 18 to 75 will take part to see if the drug shrinks tumors and to check for side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck carcinoma head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA OF HEAD AND/OR NECK

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
RECRUITING

Jinan, Shandong, 250117, China

Contact Phone: •••-•••-•••• Email: •••••@•••••